Postgraduate School in Radiodiagnostics, Università degli Studi di Milano, Via Festa del Perdono 7, 20122, Milan, Italy.
Fondazione IRCCS Istituto Nazionale dei Tumori, Via Giacomo Venezian 1, 20133, Milan, Italy.
Radiol Med. 2023 Oct;128(10):1199-1205. doi: 10.1007/s11547-023-01684-9. Epub 2023 Aug 2.
To evaluate the technical success and efficacy rates of US-guided percutaneous vacuum-assisted excision (VAE) of breast fibroadenomas, also assessing procedural complications and long-term patient satisfaction rates.
The institutional database of a tertiary breast cancer referral centre was retrospectively reviewed to retrieve all women with fibroadenomas who underwent US-guided VAE between May 2011 and September 2019. We subsequently included in this study all fibroadenomas with a maximum diameter of 3 cm at US and an available histological confirmation obtained by core-needle biopsy before VAE. Immediately after VAE, technical success (defined as the correct VAE execution) and the occurrence of procedural complications were evaluated. Imaging follow-up (US ± mammography) after 6, 12, 24 and 36 months was performed to evaluate technical efficacy (defined as the absence of fibroadenoma recurrence at 6-month follow-up). Long-term patient satisfaction was evaluated with telephonic interviews in October 2022.
We retrospectively included 108 women (median age 46 years) with 110 fibroadenomas diagnosed at core-needle biopsy with a median lesion size at US of 12 mm. Technical success was obtained in 110/110 VAEs (100%). Minor procedural complications (haematomas) occurred in 7/110 VAEs (6%), whereas 8/110 patients had a fibroadenoma recurrence at 6-month follow-up, resulting in a 93% technical efficacy (102/110 VAEs). All patients available for telephonic follow-up (104/104, 100%) reported high satisfaction with VAE results.
US-guided VAE is a safe and effective procedure for the excision of fibroadenomas, representing a viable alternative to surgery, with a low complication rate and high patient satisfaction.
评估超声引导下经皮真空辅助切除（VAE）乳腺纤维腺瘤的技术成功率和疗效，同时评估手术并发症和长期患者满意度。
回顾性分析一家三级乳腺癌转诊中心的机构数据库，以检索 2011 年 5 月至 2019 年 9 月期间所有接受超声引导下 VAE 的女性纤维腺瘤患者。我们随后纳入了这项研究的所有纤维腺瘤，这些纤维腺瘤在超声检查时的最大直径为 3cm，并且在 VAE 之前通过芯针活检获得了可获得的组织学证实。VAE 后立即评估技术成功率（定义为正确执行 VAE）和手术并发症的发生情况。在 6、12、24 和 36 个月进行影像学随访（超声±乳房 X 线摄影），以评估 6 个月随访时的技术疗效（定义为无纤维腺瘤复发）。2022 年 10 月通过电话访谈评估长期患者满意度。
我们回顾性纳入了 108 名女性（中位年龄 46 岁），共 110 个纤维腺瘤，这些纤维腺瘤在芯针活检时诊断为纤维腺瘤，超声检查的中位病变大小为 12mm。110 次 VAE 中均获得了技术成功（100%）。7 次 VAE （6%）出现轻微手术并发症（血肿），8 例患者在 6 个月随访时出现纤维腺瘤复发，技术疗效为 93%（110 次 VAE）。所有可进行电话随访的患者（104/104，100%）报告对 VAE 结果非常满意。
超声引导下 VAE 是切除纤维腺瘤的一种安全有效的方法，是手术的可行替代方法，并发症发生率低，患者满意度高。
